DBV Technologies S.A. (DBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.10 Million ≈ $-57.40 Million USD) by net assets (€207.90 Million ≈ $243.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DBV market cap for the company's overall valuation and market capitalisation.
DBV Technologies S.A. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency. See DBV Technologies S.A. (DBV) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparebank 1 Ringerike Hadeland
OL:RING
|
0.191x |
|
Mengtian Home Group Inc.
SHG:603216
|
N/A |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
N/A |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
N/A |
|
Shenzhen Liande Automatic Equipment Co Ltd
SHE:300545
|
-0.012x |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
0.059x |
|
Pantoro Gold Ltd
AU:PNR
|
0.225x |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
-0.499x |
Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. View DBV share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €168.79 Million ≈ $197.33 Million |
€-126.12 Million ≈ $-147.45 Million |
-0.747x | +80.41% |
| 2024-12-31 | €27.39 Million ≈ $32.02 Million |
€-104.47 Million ≈ $-122.14 Million |
-3.815x | -571.38% |
| 2023-12-31 | €140.19 Million ≈ $163.89 Million |
€-79.65 Million ≈ $-93.12 Million |
-0.568x | -98.41% |
| 2022-12-31 | €194.50 Million ≈ $227.39 Million |
€-55.70 Million ≈ $-65.12 Million |
-0.286x | +73.74% |
| 2021-12-31 | €99.27 Million ≈ $116.06 Million |
€-108.24 Million ≈ $-126.55 Million |
-1.090x | -65.92% |
| 2020-12-31 | €252.01 Million ≈ $294.62 Million |
€-165.61 Million ≈ $-193.61 Million |
-0.657x | +12.28% |
| 2019-12-31 | €218.05 Million ≈ $254.92 Million |
€-163.34 Million ≈ $-190.96 Million |
-0.749x | +33.50% |
| 2018-12-31 | €165.78 Million ≈ $193.81 Million |
€-186.74 Million ≈ $-218.32 Million |
-1.126x | -28.02% |
| 2017-12-31 | €182.88 Million ≈ $213.81 Million |
€-160.91 Million ≈ $-188.12 Million |
-0.880x | -258.89% |
| 2016-12-31 | €267.90 Million ≈ $313.21 Million |
€-65.68 Million ≈ $-76.79 Million |
-0.245x | -195.04% |
| 2015-12-31 | €384.24 Million ≈ $449.21 Million |
€-31.93 Million ≈ $-37.33 Million |
-0.083x | +53.34% |
| 2014-12-31 | €182.22 Million ≈ $213.04 Million |
€-32.45 Million ≈ $-37.94 Million |
-0.178x | +45.72% |
| 2013-12-31 | €74.09 Million ≈ $86.61 Million |
€-24.31 Million ≈ $-28.42 Million |
-0.328x | -23.20% |
| 2012-12-31 | €66.84 Million ≈ $78.15 Million |
€-17.80 Million ≈ $-20.81 Million |
-0.266x | +49.14% |
| 2011-12-31 | €19.79 Million ≈ $23.13 Million |
€-10.36 Million ≈ $-12.11 Million |
-0.524x | -- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more